NYSCF - Robertson Stem Cell Investigator Dr. Alex Meissner, Harvard University, analyzed the genetic patterns in cancer cells and found that disarray in the cellular on-off mechansim, known as methylation, is one of the defining characteristics of cancer and helps tumors adapt to changing circumstances.
The research, published in Cancer Cell, also showed that disorganized cell methylation had a direct impact on the effectiveness of cancer treatment in patients with chronic lymphocytic leukemia. This finding will help scientists hone in on why some tumors resist treatment and could have a large impact on all cancer analysis and treatment.
The 92nd Street Y in Manhattan hosted a panel discussion entitled, “Homo Sapiens 2.0: Genetic Enhancement and the Future of Humanity,” which covered current and future approaches to human genetic engineering and related topics. NYSCF CEO and Co-founder Susan L. Solomon sat on the panel along with George Church, PhD, professor of genetics at Harvard Medical School; Robert Klitzman, MD, professor of psychiatry and director of the masters of bioethics program at Columbia University; and Lee Silver, PhD, professor of molecular biology and public policy at Princeton University and founder of GenePeeks, Inc. The panel discussed the future of human genetics, evolution and bioethics of gene and reproductive manipulation and was moderated by Jamie Metzl, JD, PhD, senior fellow of the Asia Society.
NYSCF – Robertson Stem Cell Investigator and 2014 NYSCF – Robertson Stem Cell Prize winner Dr. Marius Wernig, Stanford University School of Medicine, made a breakthrough in treatment for a severe blistering skin disease called epidermolysis bullosa (EB).
Dr. Wernig was able to reprogram induced pluripotent stem (iPS) cells from skin samples of EB sufferers, correcting the gene mutation causing this devastating disease. This research, published in Science Translational Medicine, is the result of over five years of research and lays the groundwork for a therapeutic cellular reprogramming cure.
NYSCF and the Beyond Batten Disease Foundation (BBDF) were selected as a national innovator by the Milken Institute and presented their unique multistakeholder collaboration to find cures and treatments for juvenile Batten disease at the 6th annual FasterCures Partnering for Cures conference in New York City.
BBDF and NYSCF will develop stem cell resources to investigate and explore new treatments and, ultimately, cures for this fatal childhood illness.
NYSCF - Robertson Stem Cell Investigator Dr. Derrick Rossi, of Harvard University, published the latest from his lab on using a gene editing technique to block HIV from invading and destroying the immune system. The researhc, published in Cell Stem Cell, describes how the scientists used CRISPR-Cas gene editing technology to edit genes out of human blood-forming stem cells, making them impervious to HIV.
While this research is, at minimum, years away from reaching the clinic, it proves a promising and exciting new direction for HIV treatments and cures.
NYSCF - Robertson Stem Cell Investigator Dr. Alex Meissner, of Harvard University, published his recent analysis of whole-genome buslfate sequencing (WGBS). This sequencing method allows scientists to analyze an entire genome for DNA methylation patterns, but it remains underutilized due to high costs.
Dr. Meissner and his team used reference data to analyze miminum sequencing requirements, as compared to whole genome sequencing. The scientists identified trade-offs with increasing or decreasing sequencing coverage in their report, published in Nature Methods.
NYSCF - Druckenmiller Fellow Dr. Sandra Pinho, of Albert Einstein College of Medicine, was part of a team of scientists who recently discovered new insights into blood-forming stem cell regulation. The scientists discovered that a non-blood forming type of cell, called a megakaryocyte, can directly regulate the amount of active blood-forming stem cells in mice through the release of a specific protein.
This research helps lend insight into the regulation, maintenance, and proliferation of blood-forming stem cells, a process that is not yet fully understood. Nature Medicine published the results of the study.
NYSCF CEO Susan L. Solomon responded to "The Trials of Stem Cell Therapy," published in The New York Times on September 15, 2014 with a Letter to the Editor, refuting the article's claim that stem cell research has not delivered on its early promises of creating personalized medicine. In her letter, Ms. Solomon cited just a few of the many medical breakthroughs discovered using stem cell research in the past few years, including NYSCF's development of a cure for mitochondrial diseases, which The New York Times Magazine featured in its cover story on June 29, 2014.